Japanese encephalitis (JE), an acute inflammatory disease of the brain, is caused by infection with Japanese encephalitis virus (JEV). Children are most susceptible to JEV, which is commonly found in Asia. JEV is an enveloped RNA virus that is genetically similar to West Nile, dengue, and yellow fever viruses. No specific antiviral drugs are currently available to treat JE disease, but four types of vaccine are licensed locally to prevent JEV infection. However, the disease continues to be an important global health priority. Of the four vaccines, the most widely used in JE-endemic countries is the live-attenuated vaccine SA14-14-2. In our previous work, we cloned a genomelength cDNA of SA14-14-2 and rescued recombinant viruses entirely from the cloned cDNA (pBac/SA14-14-2). In the present study, we engineered this functional SA14-14-2 cDNA to construct a self-replicating subgenomic replicon (pBac/SA14-14-2Rep) by deleting the coding region for its two viral envelope glycoproteins, prM and E. After transfection of BHK-21 cells with the replicon RNA transcribed in vitro from pBac/SA14-14-2Rep, a combination of confocal microscopic imaging and immunoblotting showed the transient replication of the replicon RNA in the cytoplasm of RNA-transfected cells. Moreover, transfection of the SA14-14-2 replicon RNA into a BHK-21 cell line stably expressing all three JEV structural proteins (C, prM and E) led to the production of singleround infectious particles that packaged the replicon RNA, with a titter of ~105 infectious units per ml. Our SA14-14-2-based replicon represents a valuable tool for studying JEV RNA replication in low-level bio containment facilities and provides a useful platform for developing new vaccine vectors against an array of human and animal pathogens.
Sang-Im Yun, Byung-Hak Song,Young-Min Lee*
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : October 17, 2019